Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

被引:0
作者
Yong, Patrick F. K. [1 ]
Annals, Rachel [2 ]
Diwakar, Lavanya [3 ]
Elkhalifa, Shuayb [4 ]
Gompels, Mark [5 ]
Jain, Rashmi [6 ]
Karim, Mohammed Yousuf [7 ]
Khan, Sujoy [8 ]
Metcalfe, Angela [2 ]
Noorani, Sadia [9 ]
Steele, Cathal [10 ]
Kiani-Alikhan, Sorena [11 ]
Garcez, Tomaz [12 ]
机构
[1] Frimley Hlth NHS Fdn Trust, Dept Immunol, Frimley, England
[2] Hereditary Angioedema UK, Bridgwater, England
[3] Univ Hosp North Midlands NHS Trust, Dept Immunol, Stoke On Trent, England
[4] Cleveland Clin Abu Dhabi, Dept Allergy & Immunol, Abu Dhabi, U Arab Emirates
[5] North Bristol NHS Trust, Dept Immunol, Bristol, England
[6] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England
[7] Sidra Med, Hematopatho, Doha, Qatar
[8] Hull Univ Teaching Hosp NHS Trust, Dept Immunol & Allergy, Kingston Upon Hull, England
[9] Sandwell & West Birmingham NHS Trust, Dept Immunol, Birmingham, England
[10] Royal Hosp Belfast, Reg Immunol Serv, Belfast, North Ireland
[11] Royal Free London NHS Fdn Trust, Dept Immunol, London, England
[12] Manchester Univ NHS Fdn Trust, Dept Immunol, Manchester, England
关键词
hereditary angioedema; HAE; C1 inhibitor deficiency; prophylaxis; Delphi consensus; C1 INHIBITOR DEFICIENCY;
D O I
10.1093/cei/uxae020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is a rare inherited disorder causing recurrent episodes of swelling that can be potentially life threatening. Treatment of HAE can be divided into on-demand treatment for swelling, and prophylaxis. The last UK consensus on HAE was in 2014 and since then, new medications for prophylaxis have been developed, with more drugs in the pipeline. International guidelines currently recommend the use of long-term prophylaxis (LTP) as the only way of achieving disease control and normalizing patient lives. Modern prophylactic medications are available in the UK, although access is restricted primarily by HAE attack frequency. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding LTP as well as other aspects of HAE management. There was consensus that UK access criteria for modern LTP agents based on numerical frequency of attacks alone are too simplistic and potentially disadvantage a cohort of patients who may benefit from LTP. Additionally, there was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, and that the use of patient-reported outcome measures has the potential to improve patient care. Psychological health is an area in which patients may benefit, and recognition of this is important for future research and development. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding long-term prophylaxis and other aspects of hereditary angioedema management. UK access criteria for modern LTP agents based on numerical frequency of attacks alone were thought to be too simplistic, and potentially disadvantage a cohort of patients who may benefit from LTP. There was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, patient-reported outcome measures has the potential to improve patient care, and psychological support may benefit patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 50 条
  • [21] Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
    Longhurst, Hilary J.
    Dempster, John
    Lorenzo, Lorena
    Buckland, Matthew
    Grigoriadou, Sofia
    Symons, Christine
    Bethune, Claire
    Fabien, Vincent
    Bangs, Catherine
    Garcez, Tomaz
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2018, 14
  • [22] Treatment of Hereditary Angioedema: Current Perspectives
    Krassilnikova, Svetlana I.
    Nikiforov, Yuriy S.
    Craig, Timothy J.
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2008, 2 (03) : 166 - 174
  • [23] Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE
    Tachdjian, Raffi
    Banerji, Aleena
    Busse, Paula J.
    Agmon-Levin, Nancy
    Anderson, John
    Cancian, Mauro
    Spadaro, Giuseppe
    Enciu, Carmen
    Estepan, Daniel Nova
    Khutoryansky, Natalie
    Jain, Siddharth
    Recke, Andreas
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2025, 36 (04)
  • [24] Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
    V. Wahn
    W. Aberer
    W. Eberl
    M. Faßhauer
    T. Kühne
    K. Kurnik
    M. Magerl
    D. Meyer-Olson
    I. Martinez-Saguer
    P. Späth
    P. Staubach-Renz
    W. Kreuz
    European Journal of Pediatrics, 2012, 171 : 1339 - 1348
  • [25] A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
    Aygoeren-Puersuen, Emel
    Soteres, Daniel F.
    Nieto-Martinez, Sandra A.
    Christensen, Jim
    Jacobson, Kraig W.
    Moldovan, Dumitru
    Van Leerberghe, Arthur
    Tang, Yongqiang
    Lu, Peng
    Vardi, Moshe
    Schranz, Jennifer
    Martinez-Saguer, Inmaculada
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2019, 30 (05) : 553 - 561
  • [26] An update on hereditary angioedema
    Hsu, Derek
    Shaker, Marcus
    CURRENT OPINION IN PEDIATRICS, 2012, 24 (05) : 638 - 646
  • [27] Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab
    Shah, Chintal H. H.
    Princic, Nicole
    Evans, Kristin A. A.
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 871 - 877
  • [28] Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel
    Laffan, Mike
    McLaughlin, Paul
    Motwani, Jayashree
    Alamelu, Jayanthi
    Austin, Steve
    Classey, Stephen
    Dolan, Gerard
    Eales, Marie
    Gooding, Richard
    Grainger, John
    Harrison, Catherine
    Jones, April
    Kelly, Anne M.
    Oyesiku, Lara
    Rodgers, Ryan
    Stephensen, David
    Talks, Kate
    Sonecha, Shaneil
    Danquah, Andrew
    HAEMOPHILIA, 2024, 30 (02) : 306 - 319
  • [29] Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives
    Maurer, Marcus
    Magerl, Markus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (02): : 99 - 107
  • [30] Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema
    Széplaki, G
    Varga, L
    Valentin, S
    Kleiber, M
    Karádi, I
    Romics, L
    Füst, G
    Farkas, H
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (04) : 864 - 869